Dr. Russo, preeminent pharmacologist, neurologist and medical cannabis researcher, will present the findings of this important work. It is the first randomized placebo controlled clinical trail to investigate the effects of cannabigerol (CBG) on anxiety, mood, and stress and is a major step forward in demonstrating safety and efficacy of the molecule.

This webinar will:

1) Review the history and basic science of CBG.
2) Review the recent Scientific Reports article by Cuttler et al. demonstrating anti-anxiety and anti-stress responses of CBG without impairment in a randomized controlled trial
3) Provide a greater understanding of the therapeutic benefits of CBG

This seminar is FREE to those who register. A recording of the webinar will be available for educational purposes to registrants; the link will be active for 7 days after it is emailed to registrants.

Preeminent medical cannabis researcher Dr. Ethan Russo presented background and results for the first research to demonstrate the Entourage Effect. This was an informative hour learning about how vaporized D-limonene reduces Delta-9 THC-induced anxiety in healthy adults.

The webinar addressed:
1) Historical review of limonene/citrus as an antidote to cannabis over-indulgence
2) The basic science of limonene effects on the brain

Dr. Russo will also provided background and review the outcomes of the recent peer-reviewed journal article: Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.

This exciting research conducted at John Hopkins University School of Medicine and Colorado University’s (CU) Skaggs School of Pharmacy and Pharmaceutical Sciences, and the CU Department of Anesthesiology, is the first to scientifically demonstrate the Entourage Effect.

The webinar is now available for purchase and download at: https://buycredo.mm411.com/

Initial, Foundational Offering Now Available Through MM411 with Expanded Courses Planned for September

Class Tailored to Medical Professionals, Patients, Caregivers, Advocates, and Industry Workers

[May 2, 2024] – Medical Marijuana 411 (MM411), the leading global provider of digital cannabis education, today announced a groundbreaking collaboration with CReDO Science, led by Dr. Ethan Russo, a board-certified neurologist and the world’s preeminent medical cannabis clinician and researcher, to deliver accurate, evidence-based cannabis and endocannabinoid system education. An initial foundational class developed by Dr. Russo, MM411 President Christine DeVol, and Nishi Whiteley, MS, Chief Operating Officer of CReDO Science, is now available in English, Spanish, and Japanese through MM411 and features 8 webinar modules totaling 11 hours, with an expanded, follow-up class planned for September.

“We are thrilled to join forces with CReDO Science to offer this unparalleled digital cannabis education platform,” said President DeVol. “By combining our expertise in digital education with Dr. Russo’s extensive research and clinical expertise, we are poised to greatly improve the quality of cannabis education available to all as we create a legacy of his decades of groundbreaking work.”

“Cannabis has immense therapeutic potential, but misinformation and stigma often cloud its true benefits and medical use,” said Dr. Russo. “Through this collaboration with MM411 we hope to empower healthcare professionals, patients, and advocates around the globe with accurate, science-backed knowledge to fully understand the risks and benefits of cannabis use. Together, we can transform the cannabis landscape.”

Through the collaboration, Dr. Russo is distilling decades of peer-reviewed scientific studies along with his 28 years of clinical cannabis experience to ensure students receive the most accurate and up-to-date information on cannabis and its potential medical applications in a format that is comprehensible to a wide-reaching audience of medical professionals, patients, caregivers, advocates, and industry workers. As part of the experience, Dr. Russo incorporates detailed citations throughout course materials, allowing students to understand from where his lessons are based and granting them further access to the tools they will need to dive deeper.

The initial course offering aims to demystify the mechanisms by which cannabis components interact with the human body. It will make understandable the science behind cannabis and the human endocannabinoid system. This will empower healthcare professionals to integrate cannabis in their practices, patients looking to understand the science behind their treatment, and industry professionals to better serve their customers. By helping learners to make informed decisions about its use, the program will contribute to the safety and efficacy of cannabis consumption worldwide.

For more information about the collaboration between MM411 and CReDO Science and to enroll in the digital cannabis education courses, visit here. Join us on this transformative journey toward a better-informed cannabis community.

Cannabis use is growing worldwide evidenced by The United Nations World Drug Report of 2023 which estimates 219 million people worldwide use cannabis. The US government report 2022 National Survey on Drug Use and Health estimates 59 million people 18 and older used cannabis in the year prior. But cannabis education has fallen behind. According to the journal article, Physicians-in-training are not prepared to prescribe medical marijuana by Evanoff et al, 89.5% of residents and fellows graduating from American medical schools felt they were not at all prepared to prescribe medical marijuana, 35.3% felt not at all prepared to answer questions, and 84.9% reported receiving no education in medical school or residency on medical marijuana. The report further outlined only 9% of medical school curriculums included content on medical cannabis.

About MM411:

MM411 https://medicalmarijuana411.com Founded in 2009, MM411 is the global leader in medical cannabis education. Thousands of medical professionals from 20 different countries have taken MM411 research-based cannabis courses. With cannabis education programs approved by more U.S. states than any other organization, MM411 offers medical cannabis certifications and aligns with government entities to develop certification programs for medical and industry professionals, U.S. state-required certifications for healthcare professionals, and cannabis consultants (budtenders). Certifications are focused on areas such as federal and state marijuana laws, science, endocannabinoid system, approved conditions, safe handling, dispensary customer service, how to use various product methods, and dosing.

About CReDO Science: CReDO Science https://credo-science.com is a private company that offers licensing of its innovations, provides clinical cannabis research consulting and formulation and product development consulting for wellness, medical, adult-use and pharmaceutical products.

###

Media Contact:
Freeman Klopott
Fklopott@marinopr.com

The webinar covered:

• Review the history of Delta 8
• Summarize the existing science.
• Present overview of current laws & potential changes

The webinar is now available online to purchase and watch on demand: https://buycredo.mm411.com/

The Prize was established March 14, 2022, to commemorate Dr. Russo’s 70th birthday and honor his incredible contribution to the field of cannabis science.

To keep the spotlight on the critical need for research to support our burgeoning industry, Dr. Russo will talk briefly about the state of cannabis research and field general questions about cannabis, the ECS, dosing, and research.

This webinar has been made available for purchase and download here: https://buycredo.mm411.com/

Learn more about the Ethan Russo trainee prize and donate here: https://icrs.co/ICRS.ETHAN.RUSSO.TRAINEE.PRIZE.html

Dr. Ethan Russo answered questions about:

• The cannabis plant
• Cannabinoids
• Terpenes
• Endocannabinoid System (ECS)
• Existing cannabis and ECS research
• Areas of needed research
• How cannabis and cannabis products benefit certain disease states and symptoms
• Opportunities for new product development

The goal is for patients, caregivers, medical professionals, industry people, advocates and the general public to have a forum to ask general questions. Please note, specific questions about individual treatment and formulation will not be addressed. We cannot promise to answer every question but will do our best to cover as much information as possible.

This webinar has been made available for purchase to download here: https://buycredo.mm411.com/

Purchase the webinar on demand here: https://buycredo.mm411.com/

The webinar addressed:

1) Hemp roots have been used traditionally for therapeutic purposes for thousands of years.

2) Indications for hemp roots parallel those for hemp flowers despite a total lack of biochemical overlap

3) We will examine the anti-inflammatory and anti-cancer properties of hemp root triterpenoids and alkaloids

Who attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

The on-demand webinar can be purchased here: https://buycredo.mm411.com/

Purchase the webinar ondemand here: https://buycredo.mm411.com/

This webinar addressed:

1. Cannabis is one plant among many that affect the human endocannabinoid system (ECS)
2. Other plants may affect the CB1 receptor directly, or affect endocannabinoid metabolism indirectly
3. Even common foodstuffs (e.g., carrots, chocolate, black pepper, and prebiotic fibers) can affect endocannabinoid tone
4. Join us to learn how your diet affects the ECS!

Who attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

The on-demand webinar is $22.50 and is paid via PayPal. https://buycredo.mm411.com/

Austin, TX – CReDO Science and EndoCanna Health are delighted to partner to provide a screening test for cannabinoid hyperemesis syndrome (CHS). CReDO Science CEO and the inventor of the screening technology, Ethan Russo, M.D. says, “CHS previously has been an enigmatic disorder that has been a tremendous burden of abdominal pain, nausea, and vomiting for its patients. Simultaneously, it has been a diagnostic dilemma for hospital emergency departments that attempt to decipher its diagnosis with various expensive and sometimes invasive tests that usually provide little insight to the problem.”

Dr. Russo has been seeking to understand the origins of CHS for years. In 2019, his company approached Len May, the CEO of EndoCanna Health, where Dr. Russo serves as a Scientific Advisory Board member, to find that they, too, cared about solving the mystery of CHS. Dr. Russo designed and oversaw a research study executed and analyzed by EndoCanna Health which led to the discovery of five genes that appear to occur in CHS patients at significantly higher rates than the general population.  Where an individual has two or more of the five genes, it is an indication they are at much greater risk for CHS, which is triggered by chronic consumption of high THC cannabis and cannabis products.

Mr. May explains, “With the advent of this new technology, an inexpensive, simple mouth swab may provide insight to patients, their families, and physicians as to the source of the problem, and its impact.” Dr. Russo explains further the importance of this screening tool, “Our research has provided the understanding of CHS as a genetic susceptibility, and one that has implications for risks for other disorders including alcoholism, addiction to other substances, and risks for future development of heart disease and dementia, among others.”

We believe this technology will have important public health implications and offer significant savings in cost expenditures for unnecessary diagnostic tests, which patients surveyed have reported reaching $90,000-100,000. Highlighting the party’s collective intent to serve patients, Mr. May points out, “Through our HIPPA compliant process, we are able to provide the privacy patients desire with important data physicians need to aid in diagnosis and to educate patients about recovery.”

It is estimated approximately 50,000 people a year develop CHS.  That figure is expected to increase significantly as cannabis legalization occurs across more jurisdictions globally.  Some estimates for CHS prevalence have been as high as 2 million patients in the U.S., but no one knows.

Tests can be ordered by patients and physicians through the sales portal  https://shop.endodna.com/products/chs-dna-susceptibility-test. Additional information about CHS is available at www.what-is-chs.com.

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.

Endocanna Health is the industry leader in endocannabinoid system genomic testing and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.

###

This webinar addressed:

1. History and signs and symptoms of cannabinoid hyperemesis syndrome (CHS)
2. Results of the largest CHS study to date: survey responses and genomic analysis with its implications
3. Some thoughts on treatment and future direction for CHS research

Who Attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

For online access to the webinar, click here for purchasing info: https://buycredo.mm411.com/